Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Castle Biosciences
(NASDAQ:CSTL)
Intraday
$19.51
-0.35
[-1.76%]
After-Hours
$19.51
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$19.51
-0.35
[-1.76%]
At close: Apr 25
$19.51
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 7 days from now on Thu May 2nd, after the market close
Conference call scheduled in 7 days at 16:30 PM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Castle Biosciences Stock (NASDAQ:CSTL)
Castle Biosciences Stock (NASDAQ: CSTL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 04, 2024
Castle Biosciences Plans To Share New Data At The 20Th European Association Of Dermato-Oncology Congress
Benzinga Newsdesk
-
Apr 4, 2024, 4:31PM
Friday, March 22, 2024
Castle Biosciences Gives Long-Term Outcomes Data Shared At SSO 2024 Show That Patients With A Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free At 3-Years, Including Those Who Utilized The Test To Help Guide the Decision To Avoid An SLNB
Benzinga Newsdesk
-
Mar 22, 2024, 4:34PM
Friday, March 15, 2024
Castle Biosciences New Study Showing The Drug-Drug Interactions And Lifestyle Factors Provided By ' IDgenetix Test Improve Medication Recommendations Over Drug-Gene Interactions Alone For Patients 65 And Older
Benzinga Newsdesk
-
Mar 15, 2024, 4:34PM
Friday, March 08, 2024
Castle Biosciences To Present New Data Highlighting The Clinical Value Of Its Dermatologic Tests For Patients With Skin Cancer At The 2024 American Academy Of Dermatology Annual Meeting
Benzinga Newsdesk
-
Mar 8, 2024, 4:32PM
Thursday, March 07, 2024
Castle Biosciences Announced The Publication Of A New Multi-center Performance Study Of Its DecisionDx-SCC Risk Stratification Test
Benzinga Newsdesk
-
Mar 7, 2024, 7:18AM
Friday, March 01, 2024
Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $28
Benzinga Newsdesk
-
Mar 1, 2024, 3:13PM
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
Benzinga Newsdesk
-
Mar 1, 2024, 12:14PM
Thursday, February 29, 2024
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Feb 29, 2024, 2:00PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Feb 29, 2024, 12:32PM
Wednesday, February 28, 2024
Castle Bioscience Sees FY24 Revenue $235M-$240M Vs $214.693M
Benzinga Newsdesk
-
Feb 28, 2024, 5:14PM
Recap: Castle Biosciences Q4 Earnings
Benzinga Insights
-
Feb 28, 2024, 4:35PM
Castle Biosciences Q4 2023 GAAP EPS $(0.10) Beats $(0.61) Estimate, Sales $66.12M Beat $56.28M Estimate
Benzinga Newsdesk
-
Feb 28, 2024, 4:30PM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Earnings Preview For Castle Biosciences
Benzinga Insights
-
Feb 27, 2024, 12:01PM
Monday, February 26, 2024
Castle Biosciences Announced Publication Of A Study In Cancers Demonstrating That DecisionDx-Melanoma Provided Significantly Better Risk Stratification Than American Joint Committee On Cancer 8Th Edition Staging In Patients With Stage I Cutaneous Melanoma
Benzinga Newsdesk
-
Feb 26, 2024, 7:06AM
Thursday, January 18, 2024
Castle Biosciences Says New Study In Journal Of Clinical And Aesthetic Dermatology Show Its DecisionDX-SCC Test To Guide ART Decisions For Patients With Cutaneous Squamous Cell Carcinoma Could Result In Medicare Healthcare Savings Of Up To ~$972M Annually
Benzinga Newsdesk
-
Jan 18, 2024, 7:05AM
Sunday, January 07, 2024
Castle Biosciences Announces Preliminary Q4 And FY23 Results; Expects To Deliver More Than $210M For FY23 Total Revenue Vs $203.95M Est.; Year-End 2023 Cash, Cash Equivalents And Marketable Investment Securities Expected To Be ~$243M
Benzinga Newsdesk
-
Jan 7, 2024, 8:20PM
Monday, December 25, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Dec 25, 2023, 8:05AM
Thursday, December 14, 2023
Guggenheim Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $25
Benzinga Newsdesk
-
Dec 14, 2023, 6:38AM
Thursday, November 23, 2023
Massive Insider Trade At Castle Biosciences
Benzinga Insights
-
Nov 23, 2023, 10:04AM
Wednesday, November 08, 2023
Castle Biosciences, Inc. Announces Real-World Evidence Confirms IDgenetix-Guided Medication Management Significantly Improves Response And Remission Rates In Patients With Major Depressive Disorder
Benzinga Newsdesk
-
Nov 8, 2023, 5:46PM
Friday, November 03, 2023
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx-UM That Could Aid In Early Detection of Uveal Melanomas
Benzinga Newsdesk
-
Nov 3, 2023, 7:12AM
Thursday, November 02, 2023
Castle Biosciences Increases FY23 Revenue From $180M To $200M Vs $187.07M Est.
Benzinga Newsdesk
-
Nov 2, 2023, 5:59PM
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Nov 2, 2023, 5:31PM
Early Discovery Data Shows Ability Of Castle Biosciences' Pipeline Program To Distinguish Between Responders And Non-Responders To An Atopic Dermatitis Therapy
Benzinga Newsdesk
-
Nov 2, 2023, 5:24PM
Castle Biosciences Q3 2023 EPS $(0.26) Beats $(0.76) Estimate, Sales $61.49M Beat $48.52M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 4:09PM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Thursday, October 05, 2023
Castle Biosciences Announced A New Study Demonstrating DecisionDx-melanoma Outperforms A Nomogram Developed At The Memorial Sloan Kettering Cancer Center In Predicting The Risk Of Sentinel Lymph Node Positivity In Patients With Cutaneous Melanoma
Benzinga Newsdesk
-
Oct 5, 2023, 7:07AM
Monday, October 02, 2023
Castle Biosciences' Says New Data Shows Significant Clinical Utility Of Its Tissuecypher Barrett's Esophagus Test For Patients With Non-dysplastic Barrett's Esophagus At A Higher Risk Of Progression To High-grade Dysplasia Or Esophageal Adenocarcinoma
Benzinga Newsdesk
-
Oct 2, 2023, 7:11AM
Thursday, September 14, 2023
Castle Biosciences TissueCypher Barrett's Esophagus Test Outperformed Standard Of Care In Risk-Stratifying Patients With Barrett's Esophagus
Benzinga Newsdesk
-
Sep 14, 2023, 7:03AM
Sunday, September 10, 2023
Castle Biosciences Announced Late Saturday, Drug-Drug Interactions And Lifestyle Factors With Drug-Gene Interactions Provided By Castle's' IDgenetix Test Impacted the Number Of Drug Recommendations For Patients With Moderate to Severe Depression
Charles Gross
-
Sep 10, 2023, 10:44AM
Monday, August 07, 2023
Castle Biosciences Says New Study Published In The American Journal Of Gastroenterology Shows That TissueCypher Barrett's Esophagus Test Can Improve Management Decisions For Patients With Low-grade Dysplasia To Improve Health Outcomes
Benzinga Newsdesk
-
Aug 7, 2023, 7:16AM
Friday, August 04, 2023
Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $25
Benzinga Newsdesk
-
Aug 4, 2023, 4:32AM
Thursday, August 03, 2023
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
Lisa Levin
-
Aug 3, 2023, 10:57AM
Wednesday, August 02, 2023
Castle Biosciences Sees FY23 Revenue At Least $180M
Benzinga Newsdesk
-
Aug 2, 2023, 5:23PM
Castle Biosciences Q2 EPS $(0.70) Beats $(1.01) Estimate, Sales $50.14M Beat $43.51M Estimate
Benzinga Newsdesk
-
Aug 2, 2023, 4:27PM
Earnings Scheduled For August 2, 2023
Benzinga Insights
-
Aug 2, 2023, 8:45AM
Tuesday, August 01, 2023
Castle Biosciences's Earnings: A Preview
Benzinga Insights
-
Aug 1, 2023, 1:02PM
Wednesday, July 12, 2023
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Jul 12, 2023, 12:53PM
Director of Castle Biosciences Makes $1.02M Sale
Benzinga Insights
-
Jul 12, 2023, 11:02AM
Monday, July 10, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Jul 10, 2023, 1:37PM
Friday, July 07, 2023
Castle Biosciences shares are trading higher following a Medicare coverage policy reversal by Novitas related to DecisionDx.
Benzinga Newsdesk
-
Jul 7, 2023, 3:32PM
Analyst Expectations for Castle Biosciences's Future
Benzinga Insights
-
Jul 7, 2023, 3:00PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jul 7, 2023, 1:37PM
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Jul 7, 2023, 12:55PM
Alibaba, Kura Sushi USA And Other Big Stocks Moving Higher On Friday
Lisa Levin
-
Jul 7, 2023, 10:16AM
Dow Drops 75 Points; US Economy Adds 209,000 Jobs In June
Lisa Levin
-
Jul 7, 2023, 9:48AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Jul 7, 2023, 9:12AM
Lake Street Reiterates Buy on Castle Biosciences, Maintains $32 Price Target
Benzinga Newsdesk
-
Jul 7, 2023, 8:47AM
Castle Biosciences To Present New DecisionDx-SCC And DecisionDx-melanoma Data At The American Head & Neck Society's International Conference On Head And Neck Cancer
Benzinga Newsdesk
-
Jul 7, 2023, 7:03AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch